Consequently, it becomes imperative to identify effective NAMPT inhibitors that selectively target NAPRT-deficient cancers, both as monotherapy and in combination with standard chemotherapy, to overcome the challenges posed by potentially malignant tumors. Here, NAMPT is linked to cancer.